Page 6 - Secondary Progressive Multiple Sclerosis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Tiziana Life Sciences Ltd : Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis

Tiziana Life Sciences Ltd : Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Baden wübergIrina kofflerMattheww davisPaul spencerTiziana life sciences ltdBusiness developmentLifesci advisorsTiziana life sciencesMass general brigham healthcare systemSecondary progressive multiple sclerosisChief operating officerChief medical officerExpanded accessLife sciencesLife sciences ltdInvestor relations

Poised For Growth? This Biotech Is Close To Beginning Key Phase 2a Study With Its Lead Candidate - Tiziana Life Sciences (NASDAQ:TLSA)

Tiziana Life Sciences (NASDAQ: TLSA) is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and lung diseases.

National cancer instituteTiziana life sciencesSecondary progressive multiple sclerosisAmyotrophic lateral sclerosisIntranasal foralumab

FDA Okays First Biosimilar for Multiple Sclerosis

Sandoz s natalizumab-sztn injection (Tyruko) is on par with Biogen s Tysabri (natalizumab) for treatment of relapsing forms of MS, the FDA said in approving the first biosimilar to treat MS.

Paulr leeDrug administrationDivision of neurologyDrug evaluationMedscape medical newsEastern europeanExpanded disability status scaleMultiple sclerosis msMultiple sclerosisRelapsing remitting multiple sclerosisUltiple sclerosis relapsing remittingBiosimilar drugsFollow on biologicsSecondary progressive multiple sclerosisBiologic therapyUs food and drug administration

As Tiziana Life Sciences (NASDAQ: TLSA) Prepares For Phase 2 Trials, Have They Successfully Derisked Foralumab? - Bayer (OTC:BAYRY), Sanofi (NASDAQ:SNY)

Tiziana Life Sciences, Inc.

Drug administrationNational cancer institute on unsplashTiziana life sciences incTiziana life sciencesSecondary progressive multiple sclerosisDe risked phasePositron emission tomographyExpanded accessScientific advisory boardNational cancer institute

Tiziana (NASDAQ: TLSA) Continues The Fight Against Multiple Sclerosis, Will Announce 6-Month Results For Its Novel Treatment Soon - Tiziana Life Sciences (NASDAQ:TLSA), Sanofi (NASDAQ:SNY)

Tiziana Life Sciences (NASDAQ: TLSA), a clinical-stage biotechnology company focused on developing immunotherapies, will soon announce the 6-month results for patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS) receiving its novel intranasal treatment, foralumab. 

Provention bioHowardl weinerTiziana life sciencesSecondary progressive multiple sclerosisPositron emission tomographyScientific advisory